Literature DB >> 31201719

Hypoxia and the Metastatic Niche.

Cerise Yuen-Ki Chan1, Vincent Wai-Hin Yuen1, Carmen Chak-Lui Wong2.   

Abstract

Metastasis is considered the latest stage of cancer development; however, metastasis occurs earlier than it can be detected. Metastatic sites are actively remodeled by secretory factors including growth factors, chemokines and cytokines, extracellular matrix (ECM) enzymes, and exosomes produced by the primary cancer tissues. Many of the associated-secretory factors are abundantly induced by inflammation and hypoxia. These secretory factors modify the ECM, immune composition, and blood vessel permeability of the future metastatic sites, a process termed 'metastatic niche formation.' In general, ECM is modified to enhance the attachment of other cell types or cancer cells to establish a growth-factor rich metastatic niche. Immune-suppressive cells such as tumor-associated macrophages (TAMs) and regulatory T cells (Tregs) dominate the metastatic niche to allow metastatic cancer cells to bypass immune surveillance and propagate. Endothelial cell-to-cell junctions of blood vessels are loosened to enhance the penetrance of metastatic cancer cells to the metastatic sites. Different metastatic tissues have unique ECM constituents, resident immune cells, and anatomical positions linked with the circulatory system; therefore, many cancer types have their own metastatic pattern, and they favor metastasis to specific organs. Some of the remodeling events represent the earliest step of metastasis, even preceding the detachment of cancer cells from the primary tumor site. Understanding how the metastatic niche is formed is important for the development of drugs to prevent the earliest step of metastasis and advance our understanding of organotrophic metastasis. This review summarizes the major findings in the field of metastatic niche highlighting the role of hypoxia.

Entities:  

Keywords:  BMDC (bone marrow-derived cell); Chemokine; Cytokine; ECM; Exosome; MDSC (myeloid-derived suppressor cell); PMN (Premetastatic niche); TAM (tumor-associated macrophage); Treg (regulatory T cell); Tumor microenvironment

Mesh:

Year:  2019        PMID: 31201719     DOI: 10.1007/978-3-030-12734-3_7

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  9 in total

1.  Identification of Serum Exosomal hsa-circ-0004771 as a Novel Diagnostic Biomarker of Colorectal Cancer.

Authors:  Bei Pan; Jian Qin; Xiangxiang Liu; Bangshun He; Xuhong Wang; Yuqin Pan; Huiling Sun; Tao Xu; Mu Xu; Xiaoxiang Chen; Xueni Xu; Kaixuan Zeng; Li Sun; Shukui Wang
Journal:  Front Genet       Date:  2019-11-01       Impact factor: 4.599

Review 2.  Beyond immunosuppressive effects: dual roles of myeloid-derived suppressor cells in bone-related diseases.

Authors:  Zhiguo Ling; Chuan Yang; Jiulin Tan; Ce Dou; Yueqi Chen
Journal:  Cell Mol Life Sci       Date:  2021-10-11       Impact factor: 9.261

3.  Identification of a Novel Prognostic Classification Model in Epithelial Ovarian Cancer by Cluster Analysis.

Authors:  Kelie Chen; Yuequn Niu; Shengchao Wang; Zhiqin Fu; Hui Lin; Jiaoying Lu; Xinyi Meng; Bowen Yang; Honghe Zhang; Yihua Wu; Dajing Xia; Weiguo Lu
Journal:  Cancer Manag Res       Date:  2020-07-24       Impact factor: 3.989

Review 4.  The Janus Face of Tumor Microenvironment Targeted by Immunotherapy.

Authors:  Maria Buoncervello; Lucia Gabriele; Elena Toschi
Journal:  Int J Mol Sci       Date:  2019-09-03       Impact factor: 5.923

Review 5.  Metabolic Regulation of Myeloid-Derived Suppressor Cell Function in Cancer.

Authors:  Yufei Wang; Anna Jia; Yujing Bi; Yuexin Wang; Guangwei Liu
Journal:  Cells       Date:  2020-04-18       Impact factor: 6.600

Review 6.  Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy.

Authors:  Yufei Wang; Anna Jia; Yujing Bi; Yuexin Wang; Qiuli Yang; Yejin Cao; Yan Li; Guangwei Liu
Journal:  Cancers (Basel)       Date:  2020-09-15       Impact factor: 6.639

7.  Hypoxia Inducible Factor-1alpha (HIF-1A) plays different roles in Gallbladder Cancer and Normal Gallbladder Tissues.

Authors:  Youliang Wu; Delong Meng; Yexiang You; Ruochuan Sun; Min Fu; Qiang Yan; Shangxin Zhang; Zheng Fang; Junjun Bao; Yongxiang Li
Journal:  J Cancer       Date:  2021-01-01       Impact factor: 4.207

Review 8.  Fibronectin in Cancer: Friend or Foe.

Authors:  Tsung-Cheng Lin; Cheng-Han Yang; Li-Hsin Cheng; Wen-Tsan Chang; Yuh-Rong Lin; Hung-Chi Cheng
Journal:  Cells       Date:  2019-12-20       Impact factor: 6.600

Review 9.  The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis.

Authors:  Xiaobo Li; Yong Li; Weijin Lu; Minfeng Chen; Wencai Ye; Dongmei Zhang
Journal:  Cells       Date:  2019-12-10       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.